| Autor: |
Di Benedetto R; GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy., Mancini F; GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy., Carducci M; GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy., Gasperini G; GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy., Moriel DG; GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy., Saul A; GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy., Necchi F; GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy., Rappuoli R; GSK, Via Fiorentina 1, 53100 Siena, Italy., Micoli F; GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy. |
| Abstrakt: |
No commercial vaccine is yet available against Group A Streptococcus (GAS), major cause of pharyngitis and impetigo, with a high frequency of serious sequelae in low- and middle-income countries. Group A Carbohydrate (GAC), conjugated to an appropriate carrier protein, has been proposed as an attractive vaccine candidate. Here, we explored the possibility to use GAS Streptolysin O (SLO), SpyCEP and SpyAD protein antigens with dual role of antigen and carrier, to enhance the efficacy of the final vaccine and reduce its complexity. All protein antigens resulted good carrier for GAC, inducing similar anti-GAC IgG response to the more traditional CRM 197 conjugate in mice. However, conjugation to the polysaccharide had a negative impact on the anti-protein responses, especially in terms of functionality as evaluated by an IL-8 cleavage assay for SpyCEP and a hemolysis assay for SLO. After selecting CRM 197 as carrier, optimal conditions for its conjugation to GAC were identified through a Design of Experiment approach, improving process robustness and yield This work supports the development of a vaccine against GAS and shows how novel statistical tools and recent advancements in the field of conjugation can lead to improved design of glycoconjugate vaccines. |
